ARTICLE | Clinical News
Livatag: Completed Ph III ReLive enrollment
January 27, 2017 4:36 AM UTC
Onxeo S.A. (Euronext:ONXEO; CSE:ONXEO), Paris, FranceProduct: Livatag doxorubicin (Livatag doxorubicin Transdrug) (BA-003)Business: CancerMolecular target: DNADescription: Nanoparticle formulation of...
BCIQ Company Profiles